Abstract:The inflammation is the protective response of the body against various harmful stimuli; however, the aberrant and inappropriate activation tends to become harmful. The acute inflammatory response tends to resolved once the offending agent is subside but this acute response becomes chronic in nature when the body is unable to successfully neutralized the noxious stimuli. This chronic inflammatory microenvironment is associated with the release of various pro-inflammatory and oncogenic mediators such as nitric oxide (NO), cytokines [IL-1β, IL-2, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)], growth factor, and chemokines. These mediators make the inflammatory microenvironment more vulnerable toward tumorigenesis. The pro-inflammatory mediators released during the chronic inflammation tends to induce several molecular signaling cascades such as nuclear factor kappa B, MAPKinase, nuclear factor erythroid 2-related factor 2, phosphoinositide-3-kinase, Janus kinases/STAT, Wnt/B-catenin, and cyclic AMP response element binding protein. The immune system and its components have a pleiotropic effect on inflammation and cancer progression. Immune components such as T cells, natural killer cells, macrophages, and neutrophils either inhibit or enhance tumor initiation depending on the type of tumor and immune cells involved. Tumor-associated macrophages and tumor-associated neutrophils are pro-tumorigenic cells highly prevalent in inflammation-mediated tumors. Similarly, presence of T regulatory (Treg) cells in an inflammatory and tumor setting suppresses the immune system, thus paving the way for oncogenesis. However, Treg cells also inhibit autoimmune inflammation. By contrast, cytotoxic T cells and T helper cells confer antitumor immunity and are associated with better prognosis in patients with cancer. Cytotoxic T cells inflict a direct cytotoxic effect on cells expressing oncogenic markers. Currently, several anti-inflammatory and antitumor therapies are under trials in which these immune cells are exploited. Adoptive cell transfer composed of tumor-infiltrating lymphocytes has been tried for the treatment of tumors after their ex vivo expansion. Mediators released by cells in a tumorigenic and inflammatory microenvironment cross talk with nearby cells, either promoting or inhibiting inflammation and cancer. Recently, several cytokine-based therapies are either being developed or are under trial to treat such types of manifestations. Monoclonal antibodies directed against TNF-α, VEGF, and IL-6 has shown promising results to ameliorate inflammation and cancer, while direct administration of IL-2 has been shown to cause tumor regression.

Inflammation and tumor progression: signaling pathways and targeted intervention

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk

Targeting Inflammation As Cancer Therapy

Targeting the Inflammatory Pathways to Enhance Chemotherapy of Cancer

Chronic inflammation, cancer development and immunotherapy

From Inflammation to Cancer: the Molecular Basis

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Inflammation and Tumor Microenvironment.

Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms

A Signaling View into the Inflammatory Tumor Microenvironment

Inflammation,Promoting Cancer or Protecting the Body Against Cancer?

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer

Targeting The Key Factors Of Inflammation In Cancer: Plant Intervention

Inflammation and cancer: friend or foe?

NF-κB Signaling Pathway in Tumor Microenvironment

Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy

Genomic instability, inflammatory signaling and response to cancer immunotherapy

Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy

Inflammatory Cytokine: An Attractive Target for Cancer Treatment